drug
givosiran
Marketedupdated 3mo agoby $ALNY ALNYLAM PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying givosiran
- —Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria
- phase3ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
- phase2A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 20, 2026
94 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Oct 3, 2034compositionUS 10119143
- Oct 3, 2034compositionUS 11028392
- Nov 30, 2033compositionUS 9133461
- Mar 15, 2033compositionUS 10125364
- Mar 15, 2033method-of-use (U-2672)US 9631193
- Dec 12, 2029compositionUS 81060223.3y
- Dec 4, 2028compositionUS 88289562.3y
- Aug 24, 2028compositionUS 101319072.0y
FDA exclusivities (1)
- Nov 20, 2026ODE-273Orphan Drug (7y)94d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that